Children in the study will be between one month and seventeen and a half years old and will need to be on a breathing machine for more than twelve hours. They will receive one of the two sedation medications as their main treatment to keep them comfortable. Throughout their stay in the intensive care unit, doctors and nurses will regularly check for signs of delirium using a special rating scale. They will also monitor how well the sedation is working, whether the child is too sleepy or not sleepy enough, and any side effects that might occur. The study will track how long children need to stay on the breathing machine, how long they stay in the intensive care unit, and how long they remain in the hospital overall.

The study will also look at other important outcomes, including how much sedation and pain medication each child needs, whether children experience withdrawal symptoms when medications are stopped, and whether any complications occur such as low blood pressure, slow heart rate, or accidental removal of breathing tubes or other medical devices. Doctors will record if children need additional medications to treat delirium, if they need brain imaging or special tests to check brain activity, and whether they need to be put back on the breathing machine after it is removed. The study will continue to follow children for three months to understand the full impact of the different sedation approaches on their recovery and the costs of their care.

The study uses a platform design, which means it can evaluate multiple treatments at the same time. Patients will receive one or more of the study medications depending on their specific medical needs. The treatments will be given for up to 90 days while patients are in the intensive care unit.

The study will track various outcomes to determine how well the treatments work, including how long patients survive, how many days they spend without needing life support machines, how many days they spend out of the hospital, and their quality of life after treatment. The study will also monitor patients for any side effects from the medications.

The purpose of the study is to explore whether a specific approach to managing VAP, which includes daily checks to see if the infection has been cured and stopping the antibiotics if it has, is as effective as the usual treatment methods. Participants in the study will receive either the treatment with amoxicillin and clavulanic acid or a placebo. The study will monitor the participants over a period of time to observe outcomes such as survival rates, the recurrence of pneumonia, and any new episodes of VAP.

Throughout the study, researchers will also look at other factors, such as the number of days patients are free from antibiotics, the length of stay in the intensive care unit, and any side effects from the antibiotics. The study aims to provide valuable insights into the best ways to treat VAP in patients who are critically ill and require mechanical ventilation.

Participants in the study will receive either the fish oil-based treatment or a placebo. The study will monitor the occurrence of atrial fibrillation for up to seven days after surgery. Other aspects of recovery, such as the time it takes to leave the hospital and overall survival, will also be observed. The study aims to enhance recovery and improve outcomes for patients who are at high risk during heart surgery.

The trial will take place over a period of time, with participants being closely monitored for any changes in their health. The study will also look at various factors like the length of stay in the hospital, the need for additional medical support, and any complications that may arise. The goal is to gather information that could lead to better care and recovery for patients undergoing complex heart surgeries.

The purpose of the study is to compare the amount of remifentanil used between two groups of ICU patients. One group will follow a standard pain management strategy without major opioids, while the other group will follow the conventional strategy that includes opioids. The trial will observe patients from the 24th hour to the 48th hour after they are randomly assigned to one of the two groups. The study will last up to 28 days for each patient, and it aims to see if the new approach can effectively manage pain while reducing the use of opioids.

Throughout the study, researchers will monitor various aspects of the patients’ health, such as the total amount of remifentanil used, the number of days patients are free from this medication, and the number of days they are free from mechanical ventilation. Other factors being observed include the presence of any side effects like constipation or nausea, the occurrence of pneumonia related to mechanical ventilation, and the length of stay in the ICU and hospital. The study will also track the patients’ overall health status at 28 and 90 days after the trial begins.

Participants in this study will receive either Dexamethasone Phosphate, which is given as an injection, or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations. The main goal is to see if Dexamethasone Phosphate can help reduce the incidence of breathing difficulties within 48 hours after the breathing tube is removed.

The study will also look at other factors, such as the need for reintubation, which is the process of placing the breathing tube back if necessary, and the number of days children spend in the hospital. Additionally, the study will monitor any side effects that may occur from the medication. The trial is expected to run until 2027, with recruitment starting in 2024. This research is important for understanding how to better manage breathing issues in children who have been in intensive care.